The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours ...

Our immune system is great at fighting many types of cancer, but it struggles to see prostate tumors. While new treatments have been game-changers for lung cancer and skin cancer, prostate cancer ...

As expiration dates for key patents approach, the blockbuster cancer drug pembrolizumab (Keytruda) reigned as the biggest pharma moneymaker one more time, edging out the diabetes/weight-loss drug ...

A DRUG that shrinks tumours in patients with untreatable prostate cancer has shown “remarkable” results, scientists have said. The treatment, called VIR-5500, harnesses the body’s ...

Executives from Oric Pharmaceuticals (NASDAQ:ORIC) used a conference discussion to highlight near-term clinical catalysts for ...

Add Yahoo as a preferred source to see more of our stories on Google. Thousands of men suffering from prostate cancer are set to gain access to a life-extending drug on the NHS following a significant ...

Key opportunities in the prostate cancer market include innovation in androgen receptor degraders, radiopharmaceuticals, and immune-targeted therapies. Strategic collaborations and acquisitions ...

New prostate cancer drug showing ‘remarkable’ results during clinical trial - The new drug, known as VIR-5500, uses a ...

The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...

Vir Biotechnology lands a license agreement with Japan’s Astellas Pharma for its lead drug candidate.

First-line treatments for erectile dysfunction (ED) are being under-prescribed in men with prostate cancer despite strong ...